NUVL - Nuvalent, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
NUVL price evolution
NUVL
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $726.49 | $419.8 | $436.99 | $456.29 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $732.38 | $425.1 | $441.95 | $460.99 |
| Current liabilities | ||||
| Accounts payable | $9.27 | $9.8 | $8.12 | $6.43 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $31.82 | $29.1 | $20.8 | $17.02 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $31.82 | $29.1 | $20.8 | $17.02 |
| Shareholders' equity | ||||
| Retained earnings | -$286.3 | -$248 | -$214.36 | -$185.27 |
| Other shareholder equity | $0.03 | -$1.3 | -$1.54 | -$0.3 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $726.49 | $477.99 | $290.63 | $10.65 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $732.38 | $482.46 | $293.82 | $10.65 |
| Current liabilities | ||||
| Accounts payable | $9.27 | $7.2 | $2.89 | $1.25 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $31.82 | $19.48 | $8.79 | $4.38 |
| Long term debt | $2.23 | |||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $31.82 | $19.48 | $8.79 | $6.62 |
| Shareholders' equity | ||||
| Retained earnings | -$286.3 | -$160.08 | -$78.22 | -$31.89 |
| Other shareholder equity | $0.03 | -$0.49 | -$0.23 | -$0.28 |
| Total shareholder equity | ||||
| (in millions $) | 29 Oct 2022 | 29 Jul 2022 | 30 Apr 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $20.39 | $18.73 | $17.69 | $17.38 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$19.72 | -$18.47 | -$17.55 | -$17.29 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 | |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $45.82 | $16.91 | $10.36 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$46.34 | -$14.56 | -$11.81 | |
| Income (for common shares) | ||||
| (in millions $) | 29 Oct 2022 | 29 Jul 2022 | 30 Apr 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $54.74 | $37.17 | $13.06 | -$220.03 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $0.24 | -$0.76 | -$0.77 | $318.22 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $7.79 | $7.39 | -$1.25 | $58.19 |
| (in millions $) | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 | |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$220.03 | |||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $318.22 | $22.27 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | $58.19 | $7.32 | -$9.64 | |
News
Fundamentals
| Market cap | $4.13B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 64.07M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$73.02M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -56.58 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.14 |
|---|---|
| ROA | -14.18% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 22.83 |
| Quick ratio | N/A |